Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world Overall Survival in a large Italian cohort

Lung CancerAndreano A, Bergamaschi W, Russo AG, et al. | July 19, 2021

Advertisement

Researchers aimed at determining the average therapeutic effect of immune checkpoint inhibitors in any line of treatment in a 2016-2018 population-based cohort of patients with advanced non-small-cell lung cancer (NSCLC). From the cancer registry of the Agency for Health Protection of Milan, Italy, they derived cohort, and information on the tumor. They included 1,673 individuals, 324 of whom received anti PD-1/PD-L1 at any treatment line. Findings suggest correlation of treatment with anti PD–1/PD–L1 at any line with lowered hazard of death up to 2-years from date of diagnosis in this un-selected population-based cohort with advanced lung cancer. This supports the efficacy of immunotherapy outside clinical trials.

Read the full article on Lung Cancer

Advertisement